GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InterMune Inc (FRA:IUX) » Definitions » Cyclically Adjusted Revenue per Share

InterMune (FRA:IUX) Cyclically Adjusted Revenue per Share : €0.00 (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is InterMune Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

InterMune's adjusted revenue per share for the three months ended in Jun. 2014 was €0.265. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Jun. 2014.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-06-22), InterMune's current stock price is €58.06. InterMune's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2014 was €0.00. InterMune's Cyclically Adjusted PS Ratio of today is .


InterMune Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for InterMune's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InterMune Cyclically Adjusted Revenue per Share Chart

InterMune Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

InterMune Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InterMune's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, InterMune's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InterMune's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InterMune's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where InterMune's Cyclically Adjusted PS Ratio falls into.



InterMune Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, InterMune's adjusted Revenue per Share data for the three months ended in Jun. 2014 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2014 (Change)*Current CPI (Jun. 2014)
=0.265/100.5595*100.5595
=0.265

Current CPI (Jun. 2014) = 100.5595.

InterMune Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200409 0.959 80.121 1.204
200412 0.409 80.290 0.512
200503 0.670 81.555 0.826
200506 0.683 82.062 0.837
200509 0.670 83.876 0.803
200512 0.755 83.032 0.914
200603 0.620 84.298 0.740
200606 0.577 85.606 0.678
200609 0.534 85.606 0.627
200612 0.437 85.142 0.516
200703 0.451 86.640 0.523
200706 0.550 87.906 0.629
200709 0.235 87.964 0.269
200712 0.171 88.616 0.194
200803 0.154 90.090 0.172
200806 0.134 92.320 0.146
200809 0.416 92.307 0.453
200812 0.140 88.697 0.159
200903 0.128 89.744 0.143
200906 0.126 91.003 0.139
200909 0.412 91.120 0.455
200912 0.099 91.111 0.109
201003 0.086 91.821 0.094
201006 0.088 91.962 0.096
201009 0.079 92.162 0.086
201012 2.000 92.474 2.175
201103 0.080 94.283 0.085
201106 0.016 95.235 0.017
201109 0.001 95.727 0.001
201112 0.031 95.213 0.033
201203 0.105 96.783 0.109
201206 0.067 96.819 0.070
201209 0.090 97.633 0.093
201212 0.095 96.871 0.099
201303 0.096 98.209 0.098
201306 0.134 98.518 0.137
201309 0.181 98.790 0.184
201312 0.219 98.326 0.224
201403 0.241 99.695 0.243
201406 0.265 100.560 0.265

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


InterMune  (FRA:IUX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


InterMune Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of InterMune's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


InterMune (FRA:IUX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InterMune Inc (FRA:IUX) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
N/A
Address
InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

InterMune (FRA:IUX) Headlines

No Headlines